European Commission logo
English English
CORDIS - EU research results
CORDIS

Individualised and Equitable Care of Type 2 Diabetes

Project description

New database to help treat type 2 diabetes

Type 2 diabetes is the most common type of diabetes, accounting for around 90 % of all cases. It is most commonly diagnosed in older adults, but is increasingly being seen in children, adolescents and younger adults due to rising levels of obesity, physical inactivity and poor diet. Delivering high-quality patient-centred care and a personalised approach to disease management is necessary. The EU-funded EASY-Diabetes project is developing a digital health solution to ensure patients receive the most appropriate therapy. Its software-as-a-service works by providing healthcare providers access to a curated global database of clinical data and medical evidence collected over the course of nine years. Powered by machine learning algorithms and artificial intelligence, the project is preparing its go-to-market strategy.

Objective

EASY – Diabetes is a digital health solution that helps patients with Type 2 diabetes and health care providers analyse data
and make better decisions about therapies by accessing a carefully curated global database based on clinical data and
medical evidence collected over the course of nine years and powered by machine learning algorithms and other forms of
artificial intelligence. We offer EASY-Diabetes as a Software-as-a-Service to healthcare providers at a fee of €50 per patient
per year.
Diabetes is a prevalent and costly chronic disease, affecting 425 million people worldwide. Although 9.2% of the health care
budget in Europe spent on diabetes, the results for patients remain inadequate even in the most advanced healthcare
systems. Patients lack a patient-centred and personalised approach to disease management. 90% of patients with T2D are
treated by GPs in primary care. Most clinics lack both the manpower and the expertise required to deal with the needs of
patients for regular contact with health care providers and the complexity of diabetes treatment. Existing eHealth solutions
show some crucial drawbacks, such as lack of clinical validation against the standard of care, no personalised medical
treatment options, not being drug agnostic.
Our team brings together demonstrated expertise in medicine, clinical trials, drug development, regulatory affairs, product
development, programming, machine learning, business development.
The SME Phase 1 Feasibility study will aim to complete the validation of the commercial feasibility of Easy – Diabetes with
target market segments and key stakeholders. We will strengthen our financial planning and IP protection strategy
necessary to improve our service and refine our go-to-market strategy.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

ADJUVIA AB
Net EU contribution
€ 50 000,00
Address
TROLLEBERGSVAGEN 13
22229 LUND
Sweden

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00